To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes.
The bill’s titles are written by its sponsor.
Sponsor and status
Bobby Rush
Sponsor. Representative for Illinois's 1st congressional district. Democrat.
117th Congress (2021–2023)
Introduced on Jan 4, 2021
This bill is in the first stage of the legislative process. It was introduced into Congress on January 4, 2021. It will typically be considered by committee next before it is possibly sent on to the House or Senate as a whole.
Other activity may have occurred on another bill with identical or similar provisions.
18 Cosponsors (17 Democrats, 1 Republican)
Position statements
What legislators are saying
“Rush Announces His Legislative Priorities on the Opening of the 117th Congress”
—
Rep. Bobby Rush [D-IL1]
(Sponsor)
on Jan 5, 2021
History
Apr 17, 2007
|
|
Earlier Version —
Introduced
This activity took place on a related bill, H.R. 1902 (110th). |
Mar 25, 2009
|
|
Earlier Version —
Introduced
This activity took place on a related bill, H.R. 1706 (111th). |
Feb 9, 2012
|
|
Earlier Version —
Introduced
This activity took place on a related bill, H.R. 3995 (112th). |
Dec 11, 2013
|
|
Earlier Version —
Introduced
This activity took place on a related bill, H.R. 3709 (113th). |
Apr 3, 2019
|
|
Earlier Version —
Ordered Reported
This activity took place on a related bill, H.R. 1499 (116th). |
Jan 4, 2021
|
|
Introduced
Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber. |
May 4, 2021
|
|
Considered by Health
A committee held a hearing or business meeting about the bill.
|
|
If this bill has further action, the following steps may occur next: | |
—
|
|
Passed Committee
|
—
|
|
Passed House
|
—
|
|
Passed Senate
|
—
|
|
Signed by the President
|
H.R. 153 is a bill in the United States Congress.
A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
Bills numbers restart every two years. That means there are other bills with the number H.R. 153. This is the one from the 117th Congress.
How to cite this information.
We recommend the following MLA-formatted citation when using the information you see here in academic work:
“H.R. 153 — 117th Congress: Protecting Consumer Access to Generic Drugs Act of 2021.” www.GovTrack.us. 2021. May 23, 2022 <https://www.govtrack.us/congress/bills/117/hr153>
- show another citation format:
- APA
- Blue Book
- Wikipedia Template
Where is this information from?
GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.